AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
The company heralds a pivotal win with its menin inhibitor, but investors want to see data.
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.
Felmetatug vedotin’s exit could be bad news for Mersana.
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
